Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2019-03-14 AGM Information
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an Annual General Meeting (AGM) for Cha Biotech, detailing the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and specific details regarding director candidates. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2019-03-14 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted by Cha Bioitech to explain why their Annual General Meeting (AGM) is being held on a 'concentrated date' (a date when many other companies are also holding their AGMs). It provides the company name, the meeting date, the justification for the scheduling conflict, and information regarding electronic voting. Since this is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or the results of the meeting, it falls under the general regulatory filing category.
2019-03-14 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Cha Biotech. It contains the meeting agenda, voting procedures, director information, and management reports required for shareholders to prepare for the AGM. It is not a report publication announcement (RPA) because it contains the full meeting details and agenda items rather than just a link to a report. It fits the definition of AGM-R (Annual General Meeting materials).
2019-03-14 Korean
의결권대리행사권유참고서류
AGM Information Classification · 98% confidence The document is a 'Reference Document' (참고서류) for the 17th Annual General Meeting of Shareholders of CHA Biotech. It contains detailed information regarding the solicitation of proxy votes, including the list of major shareholders, the purpose of the meeting, and, crucially, the financial statements (balance sheet, income statement, statement of changes in equity, and cash flow statement) for the fiscal year 2018. Since this document is a comprehensive set of materials provided to shareholders for the purpose of the Annual General Meeting, it is classified as AGM Information.
2019-03-14 Korean
소속부변경
Regulatory Filings Classification · 95% confidence The document is a short, structured announcement regarding a change in the company's market classification (소속부변경) for Cha Biotech. It does not contain full financial statements or detailed reports, but rather serves as a regulatory notification of a status change on the exchange. As it is a specific regulatory announcement that does not fit into categories like M&A, dividends, or share issues, it falls under the general regulatory filing category.
2019-02-22 Korean
타법인주식및출자증권취득결정(자율공시)(종속회사의주요경영사항)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Decision to Acquire Shares and Securities of Another Corporation' (타법인 주식 및 출자증권 취득결정). This is a specific type of corporate disclosure related to M&A activity, specifically the acquisition of a stake in Singapore Medical Group Limited by a subsidiary. While it involves an acquisition, it is a standard regulatory disclosure of a material business event rather than a standalone M&A deal document or a general regulatory filing. Given the specific nature of the transaction (equity acquisition for market expansion), it fits best under M&A Activity (TAR).
2019-02-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.